Related Experiment Video
Updated: Mar 11, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.3K
Circulating IL-27 Is Elevated in Rheumatoid Arthritis Patients
Xiaofei Lai1, Hongxu Wang2, Ju Cao3
1Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. lxf224234@163.com.
Molecules (Basel, Switzerland)
|November 22, 2016
Summary
Elevated serum interleukin-27 (IL-27) levels are found in rheumatoid arthritis (RA) patients and correlate with disease activity. Immunosuppressive treatment reduced IL-27, suggesting its role in RA pathogenesis and potential as a biomarker.
Area of Science:
- Immunology
- Rheumatology
Background:
- Cytokines are crucial for regulating immune responses and inflammation.
- Interleukin-27 (IL-27) influences CD4+ T cell differentiation, impacting IL-10 and IL-17 secretion.
- Aberrant cytokine expression is implicated in autoimmune diseases like rheumatoid arthritis (RA).
Purpose of the Study:
- To investigate the expression of IL-27 in RA patients.
- To determine the clinical significance of IL-27 levels in RA.
- To explore the effect of immunosuppressive treatment on IL-27 levels in RA.
Main Methods:
- Serum IL-27 concentrations were measured using enzyme-linked immunosorbent assay (ELISA).
- Measurements were performed on 67 RA patients and 36 healthy controls.
- Correlations between IL-27 levels and disease activity scores (DAS28) were analyzed.
Main Results:
- Serum IL-27 levels were significantly higher in RA patients compared to controls.
- A positive correlation was observed between serum IL-27 levels and RA disease activity.
- Leflunomide treatment led to a downregulation of IL-27 levels in active RA patients.
Conclusions:
- Elevated IL-27 production contributes to the pathogenesis of RA.
- Serum IL-27 may serve as a novel biomarker for RA disease activity.
- Targeting IL-27 pathways could be a potential therapeutic strategy for RA.
Related Concept Videos
01:24T Cell Types and Functions
3.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.0K
01:20The JAK-STAT Signaling Pathway
13.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
688
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
688